NCT00324402

Brief Summary

To evaluate the maternal blood concentrations of brain natriuretic peptide (BNP) during the second and third trimesters of a normal pregnancy. We will attempt to define a normal range for pregnancy and any outliers that may serve as markers for abnormal cardiovascular physiology.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2006

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 9, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 11, 2006

Completed
3 months until next milestone

Study Start

First participant enrolled

August 1, 2006

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
Last Updated

October 5, 2020

Status Verified

October 1, 2020

First QC Date

May 9, 2006

Last Update Submit

October 1, 2020

Conditions

CardiomyopathyPregnancy

Keywords

brain natriuretic peptidepregnancybiomarker

Study Arms (1)

1

Healthy pregnant women, 18-40

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Healthy pregnant women, 18-40

You may qualify if:

  • women age 18 to 40
  • second trimester of pregnancy

You may not qualify if:

  • known cardiac or valvular disease,
  • atrial fibrillation or other arrhythmia,
  • pulmonary hypertension,
  • chronic hypertension,
  • hypertensive disorders of pregnancy,
  • morbid obesity (BMI \> 40 kg/meter squared)
  • history of sleep apnea
  • multiple gestation
  • known renal dysfunction
  • medications known to affect cardiac function
  • current or past abnormal echocardiogram

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oklahoma State University Center for Health Sciences

Tulsa, Oklahoma, 74127, United States

Location

MeSH Terms

Conditions

Cardiomyopathies

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Kimberly A Sorensen, DO

    Oklahoma State University Center for Health Sciences

    STUDY CHAIR

  • John M Beal, DO

    Oklahoma State University Center for Health Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 9, 2006

First Posted

May 11, 2006

Study Start

August 1, 2006

Study Completion

June 1, 2008

Last Updated

October 5, 2020

Record last verified: 2020-10

Locations

US(1)